Ask your doctor if AREXVY is right for you.

Booking your AREXVY vaccination starts here. Enter your postcode and find your local vaccinating pharmacist or the healthcare clinic you’re registered with.

Vaccinator information has been provided by Healthpoint. If you see any information in these listings that needs updating, email info@healthpoint.co.nz

Resources to help learn more about AREXVY

AREXVY
Patient Brochure

Suitable for printing at home
Suitable for viewing on your phone or tablet
PDF Thumbnail

AREXVY
Discussion Guide

PDF Thumbnail

Discover more about prevention of RSV through an informed conversation with your pharmacist, doctor or vaccinating nurse.

Frequently Asked Questions

Expand All Collapse All

RSV is a highly contagious respiratory virus that causes infections of the lungs and breathing passages. It usually causes mild, cold-like symptoms in healthy adults. However, it can also cause more serious respiratory illnesses and complications, such as infection of the lungs (pneumonia), in older adults.2

People aged 60 years and older, including those with certain underlying conditions such as asthma, chronic obstructive pulmonary disease (COPD), and chronic heart failure (CHF), are at increased risk for developing a severe infection from RSV. In fact, some severe RSV infections may even lead to hospitalisation.1-3,6

RSV is a contagious virus. If you are aged 60 years or older and have certain health conditions, you may be at risk for severe infections from RSV.1,2,4,6 Ask your doctor about your risk.

The seasonality of RSV can vary. In New Zealand, RSV cases typically tend to start rising in Autumn and peak in the Winter months.5,8-10

AREXVY is a vaccine that helps to protect individuals against Respiratory Syncytial Virus (RSV) infection in adults 60 years of age and older, and adults 50 through 59 who are at increased risk of RSV disease.2

In a clinical study conducted in 17 countries from the northern and southern hemispheres, AREXVY showed:

  • Over 82% EFFICACY in preventing lower respiratory tract disease from RSV in people aged 60 years and older during one RSV season.6,7
    • Overall efficacy in people ≥ 60 years old (AREXVY, 7 cases out of 12,466; placebo 40 cases out of 12,494; median follow-up 6.7 months): 82.6% (96.95% Confidence Interval: 57.9 to 94.1). In this study, RSV seasons were defined as from 1 October to 30 April in the northern hemisphere and from 1 March to 30 September in the southern hemisphere.6,7,11
  • Over 94% EFFICACY in preventing lower respiratory tract disease from RSV in people aged 60 years and older with asthma, diabetes, chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), advanced liver or kidney disease, or any chronic respiratory/pulmonary disease during one RSV season.6,7
    • Efficacy in participants with ≥1 comorbidity of interest (AREXVY, 1 case out of 4937; placebo 18 cases out of 4861; median follow-up 6.7 months): 94.6% (95% Confidence Interval: 65.9 to 99.9). In this study, RSV seasons were defined as from 1 October to 30 April in the northern hemisphere and from 1 March to 30 September in the southern hemisphere.6,7,11

AREXVY is available for people aged 60 years and older and for those adults 50 through 59 who are at increased risk of RSV disease.2,7

AREXVY is a single-dose intramuscular injection (or “shot” into a muscle) given preferably in the upper arm.2,7

All medicines can have side effects. Side effects which have been reported following administration of AREXVY include itching, pain, redness or swelling at the injection site, fever, chills, tiredness, headache, muscle pain, joint pain, a runny nose, generally feeling unwell, nausea, stomach pain and swelling of the lymph nodes.2

As with all vaccines, AREXVY may not fully protect all people who are vaccinated. AREXVY has benefits and risks – ask your healthcare professional if AREXVY is right for you.2,7

IMPORTANT SAFETY INFORMATION:2,7
You should not be given AREXVY if you are allergic to any of its ingredients. Side effects: headache, muscle pain, joint pain, tiredness and pain at the injection site. This is not a full list. Vaccination with AREXVY may not result in protection of all vaccine recipients. Ask your healthcare provider about the risks and benefits of AREXVY. Only a healthcare provider can decide if AREXVY is right for you.
References:

1. Kenmoe S;Curr Opin Infect Dis;2024;37;129-136. 2. GlaxoSmithKline New Zealand. AREXVY Consumer Medicine Information (CMI). GSK NZ; 2025 Available at https://www.medsafe.govt.nz/consumers/cmi/a/Arexvy.pdf (Accessed February 2026). 3. Branche AR;Clin Infect Dis;2022;74;1004-1011. 4. CDC;2025;1-2;RSV in Adults. 5. Obando-Pacheco P;The Journal of Infectious Diseases;2018;217;1356–1364. 6. Papi A;N Engl Med;2023;388;595-608. 7. GlaxoSmithKline New Zealand. AREXVY Data Sheet. GSK NZ; 2025. Available at https://www.medsafe.govt.nz/profs/datasheet/a/Arexvyinj.pdf (Last accessed February 2026). 8. Rose EB;MMWR Morb Mortal Wkly Rep;2018;67:71-76. 9. Immunisation Advisory Centre;2024;1-3;Respiratory syncytial virus (RSV). 10. ESR;2022;2022 ACUTE RESPIRATORY ILLNESS SURVEILLANCE REPORT. 11. Ison MG;Lancet Respir Med;2025;13(6);517-529.

VACCINATION MAY NOT PROTECT ALL RECIPIENTS7

AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older, and in adults 50 through 59 years of age who are at increased risk of RSV disease. AREXVY is a prescription medicine; it is not funded and charges will apply. A single dose (0.5 mL) contains 120 micrograms of RSVPreF3 antigen adjuvanted with AS01E, composed of the plant extract Quillaja saponaria Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (25 micrograms). AREXVY should not be administered if you are allergic to any component of this vaccine. AREXVY has risks and benefits – ask your doctor if AREXVY is right for you. Use strictly as directed. Side effects include: joint pain, injection site reactions including pain, swelling and redness, headache, runny nose, fatigue, fever and chills. This is not a full list. Vaccination with AREXVY may not fully protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor’s charges apply. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.